课题基金 / 基金详情

项目摘要

项目成果

Michael R. Farzan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (Core A – Administrative Core) The general goals of this proposal are: (1) to establish robust, consistent, and safe states of ART-free remission (‘functional cures’) in SHIV- and SIV-infected rhesus macaques through sustained expression of antibodies and antibody-like inhibitors, (2) to understand the role of the macaque immune system and antiretroviral therapy in facilitating these functional cures, and (3) to determine if these functional cures can also help accelerate the decay of the reservoir of latently infected cells. The Administrative Core will provide all the logistic, scientific, managerial, statistical, regulatory and financial support necessary to facilitate and coordinate the studies of this program, thus ensuring the successful completion of these goals. The Administrative Core will also establish and facilitate the activities of a Governing Committee with broad experience in non-human primate studies and in the application of adeno-associated virus (AAV) vectors to the treatment and prevention of viral infection. This Governing Committee will meet quarterly, twice with an appointed Scientific Advisory and NIH Program officials, and twice independently. The Administrative Core will facilitated these meetings. The Core will also promote cross-project collaborations by covering the publication costs of all manuscripts involving multi-project collaborations central to the goals of this proposal, and ensure statistical support for all studies described in this program. Finally the Core will assume responsibility for compliance with animal care and use, financial, and reporting requirements associated with this program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eCD4-mediated control of SIV infection in the brain
  • 批准号:
    10698442
  • 项目类别:
  • 资助金额:
    $91.41万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Safe, CRISPR/Cas-free B cell editing for therapeutic applications
  • 批准号:
    10725412
  • 项目类别:
  • 资助金额:
    $22.13万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
  • 批准号:
    10573644
  • 项目类别:
  • 资助金额:
    $8.28万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Targeting druggable coronavirus proteins
  • 批准号:
    10514326
  • 项目类别:
  • 资助金额:
    $578.68万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: